Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
Switch Symbol:
Year-over-year gross profit growth rate
| Period | Value |
|---|---|
| Q3 2025 | 34.85% |
| Q2 2025 | 85.95% |
| Q1 2025 | -45.98% |
| Q4 2024 | -27.45% |
| Q3 2024 | 174.27% |
| Q2 2024 | 16.48% |
| Q1 2024 | -29.33% |
| Q4 2023 | 53.85% |
| Q3 2023 | -65.24% |
| Q2 2023 | 36.66% |
| Q1 2023 | 25.04% |
| Q4 2022 | -34.38% |
| Q3 2022 | -36.31% |
| Q2 2022 | -14.29% |
| Q1 2022 | 569.44% |
| Q4 2021 | -37.88% |
| Q3 2021 | 285.13% |
| Q2 2021 | 74.59% |
| Q1 2021 | 248.08% |
| Q4 2020 | -78.33% |
| Q3 2020 | 900.00% |
| Q2 2020 | -66.67% |
| Q1 2020 | -89.84% |
| Q4 2019 | 588.35% |
| Q3 2019 | -27.97% |
| Q2 2019 | 28.83% |
| Q1 2019 | -6.72% |
| Q4 2018 | -48.03% |
| Q3 2018 | -54.20% |
| Q2 2018 | 87.97% |
| Q1 2018 | -48.35% |
| Q4 2017 | 25.30% |
| Q3 2017 | 9.31% |
| Q2 2017 | 16.77% |
| Q1 2017 | -56.37% |
| Q4 2016 | 122.29% |
| Q3 2016 | -19.22% |
| Q2 2016 | 13.85% |
| Q1 2016 | -10.86% |
| Q4 2015 | -0.74% |